Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression

HIV Clinical Trials

Volumn 10, Issue 6, 2009, Pages 432-438

  Santos, José R ^a,b   Llibre, Josep M ^a,b   Ferrer, Elena ^c   Domingo, Pere ^b   Imaz, Arkaitz ^d   Moltó, José ^a,b   Martin Iguacel, Raquel ^e   Caum, Carme ^f   Podzamczer, Daniel ^c   Clotet, Bonaventura ^a,g  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^g IrsiCaixa Foundation   (Spain)

Author keywords

Drug resistance; Enfuvirtide; HIV infections drug therapy; Multiple; Raltegravir; Viral

Indexed keywords

ANTIHISTAMINIC AGENT; EMTRICITABINE; ENFUVIRTIDE; LIPID; LIVER ENZYME; RALTEGRAVIR; TENOFOVIR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION FATIGUE; INJECTION SITE REACTION; MALE; PRIORITY JOURNAL; RASH; TREATMENT RESPONSE; VIRUS LOAD;

EID: 76749156296     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1006-432     Document Type: Article

References (24)

1. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-2185.
2. Lazzarin A, Clotet B, Cooper D, et al. efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-2195.
3. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339-354.
4. Raffi F, Battegay M, Rusconi S, et al. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS. 2007;21:1977-1980.
5. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatmentexperienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised openlabel trials. Lancet. 2006;368:466-475.
6. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29-38.
7. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39-48.
8. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429-1441.
9. Katlama C, Esposito R, Gatell JM, et al. efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21:395-402. (Pubitemid 46263249)
10. Makinson A, Reynes J. The fusion inhibitor enfuvirtide in recent antiretroviral strategies. Curr Opin HIV AIDS. 2009;4:150-158.
11. DeJesus E, Gottlieb MS, Gathe JC Jr, et al. Safety and efficacy of enfuvirtide in combination with darunavirritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of Quantification study. Antimicrob Agents Chemother. 2008;52:4315-4319.
12. Harris M, Larsen G, Montaner JS. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS. 2008;22:1224-1226.
13. Sayana S, Prosser P, Ricaurte JC, et al. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks. J Int Assoc Physicians AIDS Care. 2009;8:85-86.
14. Talbot A, Machouf N, Thomas R, et al. Retrospective analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 12 weeks in a Montreal Cohort. Presented at: 17th International AIDS Conference; August 3-8, 2008; Mexico City, Mexico. Abstract TUPE0112.
15. De Castro N, Braun J, Charreau I, et al. Switch from enfuvirtide (E) to raltegravir (R) in highly treatment-experienced HIV-1 infected patients: a randomized open-label noninferiority trial (Easier -ANRS 138). In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal. Abstract 572.
16. Towner W, Klein D, Kerrigan HL, et al. Virologic outcomes of changing Enfuvirtide to Raltegravir in HIV-1 patients well controlled on an Enfuvirtide based regimen: 24-week results of the CHEER Study. J Acquir Immune Defic Syndr. 2009;51:367-373.
17. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355-365.
18. Lennox J, Dejesus E, Lazzarin A, et al. STARTMRK, A Phase III study of the safety & efficacy of raltegravir (RAL)-based vs efavirenz (EFV)-based combination therapy in treatment-naive HIV-infected patients. In: Program and abstracts of the 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008); October 25-28, 2008; Washington, DC. Abstract H-896a.
19. Anderson MS, Sekar V, Tomaka F, et al. Pharmacokinetic (PK) evaluation of darunavir/ritonavir (DRV/r) and raltegravir in healthy subjects. Presented at: 48th Annual ICAAC / IDSA 46th Annual Meeting; October 25-28, 2008; Washington, DC.
20. Florence E, De Wit S, Castagna A, et al. Antiretroviral treatment use and HIV-RNA suppression rates for 941 European patients in the etravirine expanded access programme. Presented at: 9th International Congress on Drug Therapy in HIV Infection; November 9-13, 2008; Glasgow, UK.
21. Kerrigan H, Towner W, Klein D, et al. Treatment response among HIV patients co-enrolled in the etravirine (ETR) and raltegravir (RAL) expanded access programs (EAPs) at Kaiser Permanente. Presented at: ICAAC 48th Annual ICAAC / IDSA 46th Annual Meeting; October 25-28, 2008; Washington, DC.
22. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial. Presented at: 17th International AIDS Conference; August 3-8, 2008; Mexico City, Mexico.
23. Khanlou H, Allavena C, Billaud E, et al. Development of hepatic cytolysis after switching from enfuvirtide to raltegravir in virologically suppressed patients treated with tipranavir/ritonavir. Presented at: 17th International AIDS Conference; August 3-8, 2008; Mexico City, Mexico. Poster A-072-0082-07276 232.
24. Ribera E, Loutfy M, Florence E, et al. Switching from enfuvirtide to etravirine -efficacy results from the etravirine early access programme. Presented at: 9th International Congress on Drug Therapy in HIV Infection; November 9-13, 2008; Glasgow, UK.